AT 300 - Akashi Therapeutics/State University of New York at Buffalo

Drug Profile

AT 300 - Akashi Therapeutics/State University of New York at Buffalo

Alternative Names: AT-300; GsMtx-4

Latest Information Update: 24 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator State University of New York
  • Class Antiarrhythmics; Peptides
  • Mechanism of Action Calcium channel antagonists; Ion channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy
  • No development reported Atrial fibrillation

Most Recent Events

  • 15 Sep 2014 Akashi Therapeutics licenses global development and commercialisation rights for GsMtx 4 for Duchenne muscular dystrophy
  • 15 Sep 2014 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route)
  • 06 Nov 2002 No development reported - Preclinical for Atrial fibrillation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top